Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CEL-SCI grants Multikine licence to Teva

This article was originally published in Scrip

Executive Summary

CEL-SCI is to tap into Teva's expertise in conducting large-scale clinical studies in granting the company an exclusive licence to its cancer drug Multikine (mixed naturally derived cytokines) in Israel and Turkey. The agreement is initially restricted to head and neck cancer, the indication for which CEL-SCI is seeking to develop Multikine, but Teva can extend the agreement to other cancers during the term of the agreement. Teva is expected to participate in CEL-SCI's upcoming global Phase III trial and will fund a portion of the study and conduct part of it in Israel. Teva will also have responsibility for registering the product there. Once it is approved, CEL-SCI will be responsible for sales, and the two firms will share the revenues from the product. The Phase III trial will enrol 800 head and neck cancer patients to determine if the drug increases their survival before they receive conventional cancer treatment. In Phase II trials, Multikine was shown to be safe and well tolerated and improved patients' survival by 33% at a median of three and a half years following surgery. Head and neck cancer affects about 600,000 people per year, CEL-SCI says.

You may also be interested in...

Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts